Cannabis, Capital, and the Compounds Nobody's Talking About — with Loren DeFalco

Loren DeFalco didn't set out to run a cannabinoid-focused hedge fund. He set out to stop having seizures.After waking up in an ambulance at LaGuardia Airport in 2009, Loren spent years researching what conventional medicine couldn't fix for him — and found it in cannabinoids. That personal experience turned into CB1 Capital, a hedge fund and advisory group he has been running for close to a decade at the intersection of cannabis, finance, and drug development.In this conversation with Donna Harris, Loren covers the full landscape of where the cannabis and hemp industries stand right now — the hemp loophole closure, the long-awaited Schedule III rescheduling, the banking crisis that keeps cannabis operators off US stock exchanges while Canadian competitors list on the NYSE, and the 280E tax burden that has cannabis companies paying taxes on gross profit instead of net profit like everyone else.Then the conversation goes somewhere most cannabis discussions never reach — into the acidic cannabinoids that most people have never heard of. CBGA, CBDA, THCVA, and why Loren believes these under-researched compounds may have more therapeutic potential than anything the industry has focused on so far. Including why his LDL went from 150 to 66 after 18 months of CBGA while eating bacon, eggs, and cheeseburgers.Donna also shares the story of her mother, a half a gummy, and walking to the kitchen without her walker at midnight.This one covers a lot of ground. Worth the full listen.Loren DeFalcoCo-Founder, CB1 Capitalcb1cap.com | LinkedIn: Loren DeFalcoDonna Harris, MBA, MAccCEO, Bookkeeping Made Simple LLCmysimplebookkeeping.com | 801-692-0032